Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs AZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AZN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

AZN Overall Winner 6-Pillar Tally: CING 1 – 5 AZN Matrix Metrics: CING 1 – 9 AZN

As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas AZN carries 43.1/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin).

  • Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AZN 43.1/100 HOLD), AZN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (25.8% vs. 0.0% operating margin) and revenue trajectory (+6.7% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs AZN
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.8 · SMA20: $4.71 · SMA50: $4.82
AZN NASDAQ Head-to-Head Winner
AstraZeneca PLC
Pharmaceutical Preparations
$182.62
-0.76% 1D
Market Cap $286.1B
TTM Revenue $62.4B
Forward P/E 16.3x
Beta / 30D Vol 0.04β · 32% Vol
Unified Composite Score
43.1 / 100 HOLD
Tech 25.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.5% over 20 days), RSI 60
RSI-14: 60.0 · SMA20: $180.80 · SMA50: $169.70

6-Pillar Scorecard Institutional Category Breakdown (CING 1 – 5 AZN)

Columns: Metric · CING · AZN
1. Valuation Multiples AZN
Forward P/E N/M 16.3x
Trailing P/E N/M 26.1x
PEG Ratio N/M 1.33x
EV / Revenue N/M 4.6x
2. Growth & Scale AZN
Revenue Growth (YoY) +0.0% +6.7%
Earnings Growth (YoY) +0.0% +23.5%
TTM Revenue (USD) N/A $62.4B
Market Cap $62.5M $286.1B
3. Profitability & Quality AZN
Gross Margin N/A 81.8%
Operating Margin 0.0% 25.8%
Net Profit Margin 0.0% 17.7%
Return on Equity (ROE) -198.7% 22.6%
4. Balance Sheet & Cash Flow AZN
Cash Generation (TTM) -$21M $21.3B EBITDA
Cash Flow Margin N/A 34.1% EBITDA Mgn
Net Cash / Leverage $22M Net Cash $33.35 Book/Sh · 22.6% ROE
Dividend Yield None (0.00%) 1.75%
5. Options & Positioning CING
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.1% (16th %ile) 20.3% (8th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat AZN
OpEx & R&D Intensity N/A 56.0% of Rev ($34.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (1) vs AZN (9)
Institutional Metric CING AZN Criterion Row Edge
Market Capitalization
Scale
$62.5M $286.1B Larger Scale AZN
Trailing P/E Ratio
Valuation
N/M 26.1x Lower Multiple AZN
Forward P/E Ratio
Valuation
N/M 16.3x Lower Multiple AZN
Revenue Growth (YoY)
Growth
+0.0% +6.7% Higher Growth AZN
Operating Margin (TTM)
Profitability
0.0% 25.8% Higher Margin AZN
Net Profit Margin
Profitability
0.0% 17.7% Higher Margin AZN
Return on Equity (ROE)
Capital Efficiency
-198.7% 22.6% Higher ROE AZN
52-Week Range Position
Momentum
18% ($3–$12) 49% ($153–$213) Stronger Trend AZN
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 0.04β · 32% Vol Lower Realized Risk AZN
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 43.1 / 100 (HOLD) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
N/A $62.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.33x PEG · 4.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) $21.3B EBITDA ($33.35 Book/Sh · 22.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AZN +2.21 pp
CING: +9.17% · AZN: +11.38%
3M Horizon AZN +20.39 pp
CING: -9.68% · AZN: +10.71%
6M Horizon CING +9.53 pp
CING: +8.43% · AZN: -1.1%
1Y Horizon CING +33.91 pp
CING: +36.39% · AZN: +2.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs AZN. Trailing 12-month operating profitability (CING 0.0% vs AZN 25.8%) and valuation multiples (CING N/M vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
AZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$62.4B
Gross Margin81.8%
Op. Margin25.8%
ROE / Fwd P/E22.6% · 16.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AZN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.3%
IV Percentile 8th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AZN Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $286.1B market capitalization and 25.8% operating margin.
OpEx & R&D Reinvestment 56.0% of Rev ($34.9B)
90D Engineering Disclosures 0 Published

Investor FAQ CING vs AZN Key Questions & Quantitative Answers

As of Nov 17, 2026, AstraZeneca PLC (AZN) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas AZN carries 43.1/100 (HOLD) at $182.62 (16.3x Forward P/E, 25.8% operating margin). Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AZN 43.1/100 HOLD), AZN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (25.8% vs. 0.0% operating margin) and revenue trajectory (+6.7% vs. +0.0% YoY). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile AZN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AZN leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AZN at +6.7% YoY revenue growth and +23.5% YoY earnings growth on $62.4B TTM revenue (81.8% gross margin, 25.8% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $62.4B for AZN. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus 56.0% of Rev ($34.9B) (0 disclosures) for AZN.

AZN screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AZN trades at 16.3x Forward P/E, 26.1x Trailing P/E, 1.33x PEG, and 4.6x EV/Revenue (34.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus AZN (22.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, AZN carries 20.3% implied volatility (8th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.04β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.